Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short High-dose CHOP for Aggressive Non-Hodgkin's Lymphoma
NCT00192764Phase 2Completed
- Sponsor
- Rambam Health Care Campus
- Start
- Dec 1996
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide in diffuse large B-cell lymphoma (DLBCL), sponsored by Rambam Health Care Campus. Primary endpoint: Failure-free survival. Started Dec 1996; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00192764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00192764.